- Home
- BSBK vs COYA Comparison
BSBK vs COYA Comparison
Compare BSBK & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSBK
- COYA
- Stock Information
- Founded
- BSBK 1893
- COYA 2020
- Country
- BSBK United States
- COYA United States
- Employees
- BSBK N/A
- COYA N/A
- Industry
- BSBK Banks
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- BSBK Finance
- COYA Health Care
- Exchange
- BSBK Nasdaq
- COYA Nasdaq
- Market Cap
- BSBK 91.1M
- COYA 103.2M
- IPO Year
- BSBK N/A
- COYA 2022
- Fundamental
- Price
- BSBK $6.97
- COYA $5.93
- Analyst Decision
- BSBK
- COYA Strong Buy
- Analyst Count
- BSBK 0
- COYA 4
- Target Price
- BSBK N/A
- COYA $17.00
- AVG Volume (30 Days)
- BSBK 2.3K
- COYA 66.8K
- Earning Date
- BSBK 04-30-2025
- COYA 05-13-2025
- Dividend Yield
- BSBK N/A
- COYA N/A
- EPS Growth
- BSBK N/A
- COYA N/A
- EPS
- BSBK N/A
- COYA N/A
- Revenue
- BSBK $13,694,909.00
- COYA $3,685,107.00
- Revenue This Year
- BSBK N/A
- COYA $94.45
- Revenue Next Year
- BSBK N/A
- COYA N/A
- P/E Ratio
- BSBK N/A
- COYA N/A
- Revenue Growth
- BSBK N/A
- COYA N/A
- 52 Week Low
- BSBK $6.40
- COYA $4.65
- 52 Week High
- BSBK $8.66
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- BSBK 46.57
- COYA 48.29
- Support Level
- BSBK $6.82
- COYA $5.63
- Resistance Level
- BSBK $7.07
- COYA $6.53
- Average True Range (ATR)
- BSBK 0.13
- COYA 0.46
- MACD
- BSBK 0.02
- COYA -0.03
- Stochastic Oscillator
- BSBK 42.86
- COYA 29.70
About BSBK Bogota Financial Corp.
Bogota Financial Corp is a New Jersey-based bank. It offers personal and business banking services such as savings, certificates of deposits, online banking, loans, and many more. The Bank generally grants residential, commercial, and consumer loans to, and accepts deposits from customers in New Jersey.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.